Table 1.
Seroprevalence % | ||||||
---|---|---|---|---|---|---|
Author | Period of enrollment | Location | Tumor site | Cases (N) | Controls (N) | Adj OR (95% CI) |
Schwartz | 1990–1995 | US | Oral cavity | 51.4 (259) | 35.0 (446) | 2.3 (1.6–3.3)1 |
Oropharynx | ||||||
Herrero | 1996–1999 | International | Oral cavity | 8.9 (1,319) | 6.0 (1,527) | 1.5 (1.1–2.1)2 |
Oropharynx | 13.4 (238) | 6.0 (1,527) | 3.5 (2.1–5.9)2 | |||
Smith | 2000–2004 | US | Oral cavity | 26.8 (142) | 22.4 (326) | 1.2 (0.7–2.0)3 |
Oropharynx | 50.0 (62) | 22.4 (326) | 3.5 (1.9–6.5)3 | |||
Furniss | 1999–2003 | US | Oral cavity | 14.7 (190) | 10.7 (550) | 1.4 (0.9–2.4)4 |
Tongue, tonsil, pharynx | 40.3 (228) | 10.7 (550) | 6.0 (4.1–8.7) | |||
Pintos | 1997–2001 | Canada | Oral cavity | 6.9 (72) | 3.9 (129) | 3.9 (0.9–17.5)5 |
Base of tongue and tonsil | 12.5 (72) | 3.9 (129) | 182.3 (7–4,753)5 | |||
Sitas | 1995–2000 | South Africa | Oral cavity and pharynx | 36.3 (102) | 30.8 (2,055) | 1.5 (0.89–2.51)6 |
Oropharynx | 13.4 (238) | 6.0 (1,527) | 3.5 (2.1–5.9)6 | |||
D'souza | 2000–2005 | US | Oropharynx | 57.0 (100) | 7.0 (200) | 32.2 (14.6–71.3)7 |
All | ||||||
Gillison | 2000–2006 | US | HPV16-positive tumor | 59 (92) | 9 (184) | 18.3 (6.8–49)8 |
HPV16-negative tumor | 8 (148) | 8 (296) | 0.9 (0.4–2.2)8 |
Adjusted for age, gender, smoking, alcohol
Adjusted for age, gender, country, smoking, alcohol, paan chewing
Adjusted for age, alcohol, tobacco
Adjusted for age, race, gender, smoking, drinking
Adjusted for age, gender, tobacco, alcohol
Adjusted for age, gender, education, residence, alcohol, tobacco
Adjusted for age, gender, tobacco, alcohol, oral hygiene, family history of HNSCC
Adjusted for race, tobacco, alcohol, marijuana, dental hygiene, number of oral sex partners. Matched on age and gender